A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

Summary

This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.

Eligibility

Inclusion Criteria:

* Participants is starting avapritinib treatment at the HCP's discretion as part of their routine care (for ISM with moderate to severe symptoms inadequately controlled with symptomatic treatment) and in accordance with approved SmPC.

Exclusion Criteria:

* Participant with a potential increased risk for intracranial hemorrhage including those with a history of vascular aneurysm, intracranial hemorrhage, cerebrovascular accident within the prior year, or severe thrombocytopenia.
* Participant who has previously taken avapritinib as a commercial drug or as part of a clinical study.

Conditions2

Interventions1

Related trials

• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. — Centre Leon Berard
• Avapritinib Rollover Study — Blueprint Medicines Corporation
• Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML — Children's Hospital of Soochow University
• MRD-positive AML Clinical Study — Institute of Hematology & Blood Diseases Hospital, China
• Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation — Children's Hospital of Soochow University
• Avapritinib With Decitabine in Patients With SM-AHN — H. Lee Moffitt Cancer Center and Research Institute
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors — M.D. Anderson Cancer Center

Browse More Trials